Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Extensive Stage Lung Small Cell Carcinoma: early-phase trial registry
9 of 17 indexed Extensive Stage Lung Small Cell Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,004 of 28,707 conditions by registered trial count.
17 US clinical trials · 9 currently recruiting · #1,004 of 28,707 conditions by registered trial count
Extensive Stage Lung Small Cell Carcinoma: 17 US clinical trials tracked, 9 recruiting.
Extensive Stage Lung Small Cell Carcinoma is the subject of 17 registered US clinical trials on ClinicalTrials.gov, 9 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 16 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 7 of these trials.
Enrollment posture brief
Registry condition extensive-stage-lung-small-cell-carcinoma
OPEN 9 | RECR 53% | LATE 1 | EARLY 16 | RANK #1004 | SPON 7
Volume-matched condition peers
Nearest open-share peer: Adenoid Cystic Carcinoma (53% recruiting · 17 trials)
Extensive Stage Lung Small Cell Carcinoma lists 9 open slots (53% of 17 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Extensive Stage Lung Small Cell Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Extensive Stage Lung Small Cell Carcinoma is recruiting above its size-band peers.
9 of 17 indexed trials (52.9%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Extensive Stage Lung Small Cell Carcinoma research.
National Cancer Institute (NCI) accounts for 7 of 17 trials (41.2%). 10 distinct sponsors appear on at least one study for this condition label.
-
Most Extensive Stage Lung Small Cell Carcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 56 among the 17 trials that report a genuine target (sentinel values excluded). 11 of those (64.7%) plan for fewer than 100 participants.
-
Extensive Stage Lung Small Cell Carcinoma research is mostly interventional.
17 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
17 total, page 1 of 1
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
SWOG Cancer Research Network
NCT06769126
S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer
SWOG Cancer Research Network
NCT04155034
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
National Cancer Institute (NCI)
NCT04402788
Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer
Dwight Owen
NCT04919382
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT06287775
Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer
Asrar Alahmadi
NCT07423585
Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer
Roswell Park Cancer Institute
NCT04696575
Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer
Emory University
NCT05244239
Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation
Vanderbilt-Ingram Cancer Center
NCT06110572
Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs
National Cancer Institute (NCI)
NCT03896503
Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker
National Cancer Institute (NCI)
NCT04334941
Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial
M.D. Anderson Cancer Center
NCT04728230
Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy
Jonsson Comprehensive Cancer Center
NCT03830918
Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT05353439
LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer
City of Hope Medical Center
NCT04560972
Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT03382561
Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread
National Cancer Institute (NCI)
NCT04631029
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 8 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Extensive Stage Lung Small Cell Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Extensive Stage Lung Small Cell Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Extensive Stage Lung Small Cell Carcinoma page
17 registered trials, 9 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 9 Extensive Stage Lung Small Cell Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Extensive Stage Lung Small Cell Carcinoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Extensive Stage Lung Small Cell Carcinoma condition card totals 17 registered trials; most-linked intervention Etoposide; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.